Proactive Therapeutic Drug MONiToring to Guide Suppressive Antibiotic Therapy with DALBAvaNcin ( > 12 weeks) in Osteoarticular Infections (MONTALBANO)
Chiara Mariani, Dario Cattaneo(ASST Fatebenefratelli Sacco), Alberto Dolci(University of Milan), Simona Landonio(ASST Fatebenefratelli Sacco), Marta Colaneri(University of Milan), Marta Fusi(University of Milan), Alice Covizzi(ASST Fatebenefratelli Sacco), Matteo Passerini(University of Milan), Margherita Faenzi(ASST Fatebenefratelli Sacco), Martina Offer(University of Milan), Stefania Merli(University of Pavia), Lucia Galli(University of Milan), Andrea Gori(University of Milan)
Cited by 2
Related Papers
Immune deficiency is a risk factor for severe COVID‐19 in people living with HIV
|HIV Medicine|2020|166
Anemia in patients with Covid-19: pathogenesis and clinical significance
|Clinical and Experimental Medicine|2021|154
Real-world effectiveness and safety of glecaprevir/pibrentasvir in 723 patients with chronic hepatitis C
|Journal of Hepatology|2018|133
Incidence of Adverse Reactions in HIV Patients Treated With Protease Inhibitors: A Cohort Study
|JAIDS Journal of Acquired Immune Deficiency Syndromes|2000|115